Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

30. Dezember 2015 08:00 ET | Quelle: REGENXBIO Inc.

FDA Grants Rare Pediatric Disease Designation to REGENXBIO's RGX-111 Gene Therapy for the Treatment of Mucopolysaccharidosis Type I (MPS I)

ROCKVILLE, Md., Dec. 30, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant...
18. Dezember 2015 16:15 ET | Quelle: REGENXBIO Inc.

REGENXBIO Added to Russell 2000(R) Index

ROCKVILLE, Md., Dec. 18, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant...
01. Dezember 2015 09:11 ET | Quelle: REGENXBIO Inc.

REGENXBIO to Participate in Upcoming Investor and Scientific Conferences

ROCKVILLE, Md., Dec. 1, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant...
05. November 2015 08:02 ET | Quelle: REGENXBIO Inc.

REGENXBIO Reports Third Quarter 2015 Results

ROCKVILLE, Md., Nov. 5, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant...
15. Oktober 2015 08:01 ET | Quelle: REGENXBIO Inc.

Dr. David C. Stump Appointed to REGENXBIO Board of Directors

ROCKVILLE, Md., Oct. 15, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company in gene therapy, today announced the appointment of David C. Stump, M.D., to its board...
01. Oktober 2015 17:05 ET | Quelle: REGENXBIO Inc.

FDA Grants Orphan Drug Designation to REGENXBIO's RGX-111 Gene Therapy for the Treatment of Mucopolysaccharidosis Type I (MPS I)

ROCKVILLE, Md., Oct. 1, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (REGENXBIO) (Nasdaq:RGNX), a leading biotechnology company in gene therapy, today announced that the U.S. Food and Drug Administration...
22. September 2015 16:02 ET | Quelle: REGENXBIO Inc.

REGENXBIO Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

ROCKVILLE, Md., Sept. 22, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company in gene therapy, today announced the closing of its initial public offering of...
16. September 2015 20:29 ET | Quelle: REGENXBIO Inc.

REGENXBIO Announces Pricing of Initial Public Offering

ROCKVILLE, Md., Sept. 16, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc. ("REGENXBIO"), a leading biotechnology company in gene therapy, today announced the pricing of its initial public offering of...
11. Juni 2015 08:00 ET | Quelle: REGENXBIO Inc.

REGENXBIO Enters Into Strategic Manufacturing Collaboration With Wuxi Apptec

ROCKVILLE, Md. and SHANGHAI, China, June 11, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc., a leading biotechnology company in gene therapy, today announced that it has entered into an exclusive strategic...
27. Mai 2015 09:00 ET | Quelle: REGENXBIO Inc.

Dr. Jerry Karabelas Appointed to REGENXBIO Board of Directors

ROCKVILLE, Md., May 27, 2015 (GLOBE NEWSWIRE) -- REGENXBIO Inc., a leading biotechnology company in gene therapy, today announced the appointment of Jerry Karabelas, Ph.D., to its board of...

Vorherige Seite

Nächste Seite